Opposite findings

The results of two clinical studies on EHRs offered interesting and opposite findings.

While a study found that alerts in EHR systems that prompt providers to begin or continue the human papilloma virus (HPV) vaccination with pediatric patients lead to an increased rate of protection against cervical cancer, another study found that ischemic stroke patients at hospitals with EHR systems did not have better illness progression or care quality than similar patients at hospitals without EHRs.

The stroke study found no difference in patients' quality of care and illness progression between hospitals with EHRs and those without EHRs, including after adjusting the data for certain patient characteristics. However, patients who received care at hospitals with EHRs were slightly less likely to have prolonged hospital stays of more than four days. 

In an accompanying editorial, John Windle, chief of cardiology at the University of Nebraska Medical Center, wrote that the study "is a wake-up call that we should heed." EHR systems' top priority "must be support of clinical care, not documentation for billing and reimbursement."

Here’s hoping for more clinical studies that show the value of EHRs and health IT rather than provide more ammunition against digitization.

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.